Taiwanese Journal of Obstetrics and Gynecology
Volume 45, Issue 2 , Pages 120-123, June 2006

Outcome of Pregnancy in Patients with Systemic Lupus Erythematosus

  • Chiong-Hee Wong

      Affiliations

    • Department of Rheumatology, Mackay Memorial Hospital, Taipei, Taiwan
    • ,
  • Tien-Ling Chen

      Affiliations

    • Department of Rheumatology, Mackay Memorial Hospital, Taipei, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Tien-Ling Chen, Department of Rheumatology, Mackay Memorial Hospital, 92, Section 2, Chung-Shan North Road, Taipei, Taiwan
    • ,
  • Chyou-Shen Lee

      Affiliations

    • Department of Rheumatology, Mackay Memorial Hospital, Taipei, Taiwan
    • ,
  • Chen-Ju Lin

      Affiliations

    • Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan
    • ,
  • Chih-Ping Chen

      Affiliations

    • Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan

Accepted 10 April 2005.

Article Outline

Summary 

Objective

To study the maternal and fetal outcomes in women with systemic lupus erythematosus (SLE).

Materials and Methods

Over a period of 10 years, 24 pregnancies in 17 females with SLE in a single center were enrolled. Fetal and maternal outcomes were studied retrospectively.

Results

The mean patient age was 27.7 years. Twenty-one of the 24 pregnancies occurred in the period of disease remission at the time of conception. Proteinuria presented in 12 pregnancies; however, no patient developed acute renal failure or deterioration of renal function. There were three cases of preeclampsia in this study. Two patients had their disease flare up and delivered stillborns. One woman with secondary antiphospholipid syndrome (APS) had a fetal loss. There was no maternal mortality. The mean gestation age was 34.3 weeks (range, 17-41 weeks), and the mean birth weight was 2,179 g. The mean APGAR scores were 8 and 9 at 1 and 5 minutes, respectively. One baby with congenital atrioventricular block was born to a mother with positive anti-SSA antibody. There were five cases (20.8%) of intrauterine growth retardation and 10 preterm deliveries (41.6%) in this study.

Conclusion

Pregnancy is relatively safe in women with SLE in remission but should be considered as a high-risk pregnancy. APS is associated with poor pregnancy outcome. The patient needs to cooperate with obstetricians and physicians for optimal disease control and detailed monitoring throughout the gestation.

Key Words:  outcome , pregnancy , systemic lupus erythematosus

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Petri M , Howard D , Repke J . Frequency of lupus flare in pregnancy: The Hopkins Lupus Pregnancy Center Experience . Arthritis Rheum . 1991;34:1538–1545
  2. Petri M . Prospective study of systemic lupus erythematosus pregnancies . Lupus . 2004;13:688–689
  3. Lockshin MD . Pregnancy does not cause systemic lupus erythematosus to worsen . Arthritis Rheum . 1989;32:665–670
  4. Kiss E , Bhattoa HP , Bettembuk P , Balogh A , Szegedi G . Pregnancy in women with systemic lupus erythematosus . Eur J Obstet Gynecol Reprod Biol . 2002;101:129–134
  5. Georgiou PE , Politi EN , Katsimbri P . Outcome of lupus pregnancy: a controlled study . Rheumatology . 2000;39:1014–1019
  6. Gordon C . Pregnancy and autoimmune diseases . Best Pract Res Clin Rheumatol . 2004;18:359
  7. Le Huong D, Wechsler B, Vauthier-Brouzes D, Seebacher J, Lefebvre G, Bletry O, et al. Outcome of planned pregnancies in systemic lupus erythematosus: a prospective study on 62 pregnancies . Br J Rheumatol . 1997;36:772–777
  8. Moroni G , Quaglini S , Banfi G . Pregnancy in lupus nephritis . Am J Kidney Dis . 2002;40:713–720
  9. Brucato A, Doria A, Frassi M, Castellino G, Franceschini F, Faden D, et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study . Lupus . 2002;11:716–721
  10. Petri M . Pregnancy in SLE . Baillieres Clin Rheumatol . 1998;12:449–476
  11. Ruiz-Irastorza G , Khamashta MA , Gordon C . Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale . Arthritis Rheum . 2004;51:78–82
  12. Ostensen M . Disease specific problems related to drug therapy in pregnancy . Lupus . 2004;13:746–750
  13. Ostesen M . Optimisation of antirheumatic drug treatment in pregnancy . Clin Pharmacokinet . 1994;27:486–503
  14. Borden MB , Parke AL . Antimalarial drugs in systemic lupus erythematosus: use in pregnancy . Drug Saf . 2001;24:1055–1063
  15. Costedoat-Chalumeau N , Amoura Z , Aymard G , et al.   Evidence of transplacental passage of hydroxychloroquine in humans . Arthritis Rheum . 2002;46:1123–1124
  16. Levy RA , Vilela VS , Cataldo MJ , et al.   Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study . Lupus . 2001;10:401–404
  17. Costedoat-Chalumeau N , Amoura Z , Duhaut P . Safety of hydroxychloroquine in pregnant patients with connective tissue diseases . Arthritis Rheum . 2003;48:3207–3211
  18. Lockshin MD , Sammaritano LR . Corticosteroids during pregnancy . Scand J Rheumatol Suppl . 1998;107:136–138
  19. Carmichael SL , Shaw GM . Maternal corticosteroid use and risk of selected congenital anomalies . Am J Med Genet . 1999;86:242–244
  20. Carmona F , Font J , Cervera R , Munoz F , Cararach V , Balasch J . Obstetrical outcome of pregnancy in patients with systemic lupus erythematosus. A study of 60 cases . Eur J Obstet Gynecol Reprod Biol . 1999;83:137–142
  21. Petri M . Immunosuppressive drug use in pregnancy . Autoimmunity . 2003;36:51–56

PII: S1028-4559(09)60208-4

doi:10.1016/S1028-4559(09)60208-4

Taiwanese Journal of Obstetrics and Gynecology
Volume 45, Issue 2 , Pages 120-123, June 2006

Article Tools